Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

Impact · against what's priced in

Verastem presents a positive outlook driven by strong early commercial traction for the Avmapki Fakzynja Co-pack and a high-impact clinical catalyst in October. While the revenue run rate is promising, the primary valuation driver is the upcoming VS-7375 readout.

VSTM+0.70

No priced-in read yet

In context

The $25.1M Q2 revenue run rate for the Co-pack demonstrates rapid commercial adoption, while the October TARGET-D 101 readout for VS-7375 provides a concrete near-term catalyst for the KRAS G12D pipeline.

Read from the article alone

• biotech
• VSTM
• cancer research
• clinical catalyst
• clinical trials
• kras inhibitor
• oncology
• product revenue

Search tags